Present Directions in the Investigation of Dimethoxyphenethylamine

  • Arnold J. Friedhoff


Over the past ten years, tremendous advances have been made in the basic understanding of the biological substratum of mental processes. This has been reflected by increased understanding of the metabolism of neurohormones, the genetics of mental illness, the structure activity relationship of hallucinogens and the possible mechanism of action of psychopharmacological agents. Stemming from this new understanding have been a number of new techniques for the study of biochemical processes, and as a result of these techniques, several investigations of biochemical abnormalities related to schizophrenia have been undertaken which were not previously possible. All of these advances have given great forward momentum to the field of biological psychiatry, and it should be necessary to detail only a few to demonstrate this point.


Mental Illness Schizophrenic Patient Phenylacetic Acid Tremendous Advance Structure Activity Relation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bergen, J.R., Possible relationship of a plasma factor to schizophrenia, Trans. N.Y. Acad. Sci., 28, 40–46, 1965.PubMedCrossRefGoogle Scholar
  2. 2.
    Bourdillon, R. E. and Ridges, A. P., 3,4-Dimethoxyphenylethylamine in schizophrenia? In: Amines and Schizophrenia, Himwich, Kety and Smvthies (Eds.), Pergamon Press, Oxford, 1967.Google Scholar
  3. 3.
    Creveling, C. R. and Daly, J. W., Identification of 3,4-dimethoxyphenylethylamine from schizophrenic urine by mass spectrometry, Nature, 216, 190–191, 1967.PubMedCrossRefGoogle Scholar
  4. 4.
    Faurbye, A. and Pind, K., Investigation on the occurrence of the dopamine metabolite, 3,4-dimethoxyphenylethylamine, Acta Psychiat. Scand., 40, 240–243, 1964.PubMedCrossRefGoogle Scholar
  5. 5.
    Friedhoff, A. J., Metabolism of dimethoxyphenethylamine and its possible relationship to schizophrenia. In: Origins of Schizophrenia, Romano (Ed.), Excerpta Medica Internat’l Cong. Ser., 151, 27–34, 1968.Google Scholar
  6. 6.
    Friedhoff, A. J. and Furiya, K., 3,4-Dimethoxyphenylacetic acid in urine, Nature, 214, 1127–1128, 1967.PubMedCrossRefGoogle Scholar
  7. 7.
    Friedhoff, A. J. and Van Winkle, E., Isolation of a compound from the urine of schizophrenics, Nature, 194, 897–898, 1962 a.CrossRefGoogle Scholar
  8. 8.
    Friedhoff, A. J. and Van Winkle, E., New Developments in the investigation of the relationship of 3,4-dimethoxyphenethylamine to schizophrenia. In: Amines and Schizophrenia, Himwich, Kety & Smythies (Eds.), Pergamon Press, Oxford, 1966.Google Scholar
  9. 9.
    Friedhoff, A. J. and Van Winkle, E., The characteristics of an amine found in the urine of schizophrenic patients, J. Nerv. Ment. Dis., 135, 550–555, 1962 b.PubMedCrossRefGoogle Scholar
  10. 10.
    Kuehl, F. A., Ormond, R. E. and Vandenheuvel, W. J. A., Occurrence of 3,4-dimethoxyphenylacetic acid in the urines of normal and schizophrenic individuals, Nature, 211, 606, 1966.PubMedCrossRefGoogle Scholar
  11. 11.
    Nordio, S., Berio, A. and Distefano, A., Pink spot and other amines in urine, Lancet, 2, 311–312, 1967.CrossRefGoogle Scholar
  12. 12.
    Perry, T. L., Hansen, S. and Macintyre, L., Failure to detect 3,4-dimethoxyphenylethylamine in the urine of schizophrenics, Nature, 202, 519–520, 1964.PubMedCrossRefGoogle Scholar
  13. 13.
    Predescu, V., Florescu, D. and Radulescu, C., Pink spot as a diagnostic test in schizophrenia, Nature, 217, 1150–1151, 1968.PubMedCrossRefGoogle Scholar
  14. 14.
    Proctor, C. D., Cho, J. B., Ashley, L. G., Potts, J. L., Eaton, H. E., McGriff, J. E., Douglas, J. G. and Amoroso, C. P., Factors influencing a blood plasma-DMPEA test for schizophrenia, Fedn. Proc., 27, 219, 1968.Google Scholar
  15. 15.
    Ridges, A. P. and Bourdillon, R. E., Schizophrenia, transmethylation and pink spot, Proc. Royal Soc. Med., 60, 555–560, 1966.Google Scholar
  16. 16.
    Sen, N. P. and McGeer, P. L., 4-Methoxyphenylethylamine and 3,4-dimethoxyphenylethylamine in human urine, Biochem. Biophys. Res. Commun., 14, 227, 1964.PubMedCrossRefGoogle Scholar
  17. 17.
    Takesada, M., Kakimoto, Y., Sano, I. and Kaneko, Z., 3,4-Dimethoxyphenylethylamine and other amines in the urine of schizophrenic patients, Nature, 199, 203–204, 1963.PubMedCrossRefGoogle Scholar
  18. 18.
    Vacca, L., Fujimori, M., Davis, S. H. and Marrazzi, A., Cerebral synaptic transmission and behavioral effects of dimethoxyphenylethylamine: A potential psychotogen, Science, 160, 95–96, 1968.PubMedCrossRefGoogle Scholar
  19. 19.
    Vogel, W. H., Ahlberg, C. D. and Horwitt, M. K., Time study of the urinary excretion of 3,4-dimethoxyphenylethylamine and 3,4-dimethoxyphenylacetic acid by schizophrenic and normal individuals, Internat. J. Psychiat., 3, 292–297, 1967.Google Scholar

Copyright information

© Springer Science+Business Media New York 1969

Authors and Affiliations

  • Arnold J. Friedhoff

There are no affiliations available

Personalised recommendations